These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34382434)

  • 1. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis.
    Damask C; Chen M; Holweg CTJ; Yoo B; Millette LA; Franzese C
    Am J Rhinol Allergy; 2022 Jan; 36(1):135-141. PubMed ID: 34382434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
    Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
    Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
    Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
    J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
    Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
    Gevaert P; Saenz R; Corren J; Han JK; Mullol J; Lee SE; Ow RA; Zhao R; Howard M; Wong K; Islam L; Ligueros-Saylan M; Omachi TA; Bachert C
    J Allergy Clin Immunol; 2022 Mar; 149(3):957-965.e3. PubMed ID: 34530020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps.
    Braid J; Islam L; Gugiu C; Omachi TA; Doll H
    World Allergy Organ J; 2023 May; 16(5):100776. PubMed ID: 37214171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study.
    Armengot-Carceller M; Gómez-Gómez MJ; García-Navalón C; Doménech-Campos E; Muñoz-Fernández N; Miguel AG; Marco-Algarra J; Palop-Cervera M; Piñero AG
    Am J Rhinol Allergy; 2021 Jul; 35(4):516-524. PubMed ID: 33153272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
    Wu Q; Zhang Y; Kong W; Wang X; Yuan L; Zheng R; Qiu H; Huang X; Yang Q
    Int Arch Allergy Immunol; 2022; 183(3):279-288. PubMed ID: 34607329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab improves sleep and health status for patients with chronic rhinosinusitis with nasal polyps: An analysis of randomized clinical trials.
    Meltzer EO; Mullol J; Ko J; Saenz R; Steinke JW; Millette LA; Gevaert P
    Int Forum Allergy Rhinol; 2024 Jul; 14(7):1163-1172. PubMed ID: 38197558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
    De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
    Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
    Miglani A; Soler ZM; Smith TL; Mace JC; Schlosser RJ
    Int Forum Allergy Rhinol; 2023 Feb; 13(2):116-128. PubMed ID: 35980852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Omalizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Severe Allergic Asthma.
    Atayik E; Aytekin G; Aydin İ; Omeroglu E
    Iran J Allergy Asthma Immunol; 2024 May; 23(3):245-256. PubMed ID: 39422385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye.
    Demir M; Tunakan Dalgic C; Mete Gokmen EN; Savas R; Eroglu S; Ozden G; Orcen C; Pacaci Cetin G; Arslan B; Bilgir F; Bulut G; Akcam NY; Ozgul S; Cerci P; Coskun R; Gode S; Yilmaz I; Sin AZ
    Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541174
    [No Abstract]   [Full Text] [Related]  

  • 14. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease].
    Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study.
    Maza-Solano J; Callejon-Leblic A; Martin-Jimenez D; Moreno-Luna R; Gonzalez-Garcia J; Cuvillo A; Sanchez-Gomez S
    Curr Allergy Asthma Rep; 2023 Oct; 23(10):555-566. PubMed ID: 37644255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
    Rivero A; Liang J
    Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
    Bachert C; Mannent L; Naclerio RM; Mullol J; Ferguson BJ; Gevaert P; Hellings P; Jiao L; Wang L; Evans RR; Pirozzi G; Graham NM; Swanson B; Hamilton JD; Radin A; Gandhi NA; Stahl N; Yancopoulos GD; Sutherland ER
    JAMA; 2016 Feb; 315(5):469-79. PubMed ID: 26836729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxycycline may be more clinically effective in type 2 chronic rhinosinusitis nasal polyp comorbid with asthma.
    Paçacı Çetin G; Arslan B; Yılmaz İ
    J Asthma; 2024 Jan; 61(1):20-26. PubMed ID: 37437223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
    Tversky J; Lane AP; Azar A
    Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.